The Week Ahead: COS...
Health Care: Drugs
Eli Lilly and Company (LLY: NYSE)
$54.14 -0.60 | -1.10%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 4.09B | 4.35B | 5.07B | 4.33B |
| Operating Gains/Losses | 0.00 | 0.00 | -79.80M | -1.31B |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 361.80M | -188.80M | -319.10M | -492.90M |
| (Increase) Decrease in Inventories | -307.90M | 203.10M | 157.00M | -179.00M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 340.50M | -84.90M |
| (Decrease) Increase In Payables | -336.10M | 591.40M | -363.90M | -200.10M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 231.00M | 642.70M | 0.00 | 0.00 |
| Other Non-Cash Items | -320.80M | 533.30M | 164.70M | 789.50M |
| Net Cash From Continuing Operations | 5.30B | 7.23B | 6.86B | 4.34B |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 5.30B | 7.23B | 6.86B | 4.34B |
| Sale of Property, Plant & Equipment | 1.23B | 25.30M | 24.60M | 17.70M |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -1.04B | -1.69B | -1.19B | -855.00M |
| Acquisitions | -199.30M | -307.80M | -609.40M | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 439.50M | -528.10M | -905.80M | -94.50M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -2.83B | -4.82B | -3.16B | 142.80M |
| Issuance of Debt | 0.00 | 0.00 | 1.20M | 2.40B |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Repayment of Long-Term Debt | -1.50B | -54.60M | -1.10M | -5.82B |
| Repurchase of Capital Stock | -721.10M | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | -2.19B | -2.18B | -2.17B | -2.15B |
| Other Financing Charges, Net | -10.50M | -135.20M | 143.30M | 42.60M |
| Net Cash From Financing Activities | -4.42B | -2.37B | -2.02B | -5.53B |
| Effect of Exchange Rate Changes | 43.90M | -110.90M | -144.80M | 21.60M |
| Net Change in Cash & Cash Equivalents | -1.90B | -70.70M | 1.53B | -1.03B |
Portfolios with LLY
- Portfolio NameUser Type
- ContributorHigh Volume Technicals for ...
- ProRenaissance Technologies
- Contributor8 Stocks With Big Dividends...
- ContributorStocks Rising On Unusual Vo...
- ContributorRocket Stocks for the Week ...
- UserJS&JH
- Contributor5 Bullish Stocks to Buy on ...
- UserBG Stockpickr Wish List
- UserStock Interests, Ideas & Re...
- Contributor7 High-Yield Stocks With Bu...
Latest LLY Headlines from TheStreet
- Eli Lilly And Company (LLY): Today's Featured Drugs Laggard 05.24.13 | 05:05 pm
- Eli Lilly And Company Stock Buy Recommendation Reiterated (LLY) 05.21.13 | 10:05 am
- AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward 05.16.13 | 01:05 pm
- Eli Lilly And Company (LLY): Today's Featured Drugs Winner 05.15.13 | 05:05 pm
- 4 Stocks Going Ex-Dividend Tomorrow: GIL, ACC, ADM, LLY 05.13.13 | 10:05 am
- Eli Lilly And Stock To Go Ex-dividend Tomorrow (LLY) 05.13.13 | 09:05 am
- 4 Stocks Pushing The Drugs Industry Downward 05.07.13 | 01:05 pm
- It's Pipeline That Matters Most 05.04.13 | 04:05 am
- Cramer's 'Mad Money' Recap: Good Earnings, Bad Market 05.01.13 | 08:05 pm
- Eli Lilly And Company (LLY): Today's Featured Health Care Laggard 04.30.13 | 05:04 pm
Press Releases for LLY
- Lilly Acquires Novel Tau Tangle Diagnostic Program To Bolster Alzheimer's Disease Research And Development - PR Newswire 04.17.13 | 08:04 am
- Lilly Announces Positive Results Of Phase III Trials Of Dulaglutide In Type 2 Diabetes - PR Newswire 04.16.13 | 08:04 am
- Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles For Recoupment Policies Covering Major Compliance Failures - PR Newswire 04.04.13 | 08:04 am
- Lilly Confirms Date And Conference Call For First-Quarter 2013 Financial Results Announcement - PR Newswire 04.03.13 | 04:04 pm
- Potential Lilly Investment Would Further Expand Indianapolis Insulin Manufacturing Operations - PR Newswire 04.02.13 | 08:04 am
- European Medicines Agency Accepts Marketing Authorization Application For Boehringer Ingelheim And Eli Lilly And Company's Empagliflozin*, An Investigational Type 2 Diabetes Treatment - PR Newswire 03.26.13 | 11:03 am
- Boehringer Ingelheim And Eli Lilly And Company Submit New Drug Application To FDA For Empagliflozin, An Investigational Type 2 Diabetes Treatment - PR Newswire 03.25.13 | 08:03 am
- Boehringer Ingelheim And Lilly Initiate MARLINA Clinical Trial To Evaluate Use Of Tradjenta® (linagliptin) Tablets In Patients With Type 2 Diabetes And Albuminuria - PR Newswire 03.19.13 | 08:03 am
- New Study Of Cialis® (tadalafil) Tablets Co-administered With Finasteride Meets Primary Endpoint In Men With Lower Urinary Tract Symptoms Of Benign Prostatic Hyperplasia - PR Newswire 03.18.13 | 11:03 am
- New Superiority Trial Showed LIVALO® (pitavastatin) 4 Mg Provided Significantly Greater LDL-C Reduction In HIV-Infected Adults With Dyslipidemia Versus Pravastatin 40 Mg - PR Newswire 03.07.13 | 06:03 am
Partner Headlines for LLY
- J&J Q1 Earnings Beat; Pharma Strong, Devices Weak - Investor's Business Daily 04.16.13 | 04:04 pm
- Parexel Grows Earnings With Big Pharma Partnerships - Investor's Business Daily 04.04.13 | 02:04 pm
- Can New Psoriasis Drugs Scratch Investors' Itch? - Investor's Business Daily 04.04.13 | 01:04 pm
- Is the New Abbot a Winner? - Wall St. Cheat Sheet 04.02.13 | 10:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- 6 Stocks To Accumulate For A High-Yield Stable Portfolio - Seeking Alpha 02.26.13 | 09:02 am
- 2013, A Year Of Turmoil For Eli Lilly - Seeking Alpha 02.16.13 | 09:02 am
- FDA rejects Novo Nordisk insulin remedy - Financial Times 02.12.13 | 12:02 am
- Novo Nordisk Hit By Diabetes Drug Delay; Sanofi Rises - Investor's Business Daily 02.11.13 | 05:02 pm
- Novo Nordisk: reality check - Financial Times 02.11.13 | 04:02 pm
